Journal
DRUG DISCOVERY TODAY
Volume 22, Issue 1, Pages 186-193Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2016.08.006
Keywords
-
Categories
Funding
- American Heart Association [16GRNT30950010]
- National Institutes of Health COBRE grant [P20GM104936]
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM104936] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Macrophages are a heterogeneous population of phagocytic cells present in all tissues. Recently, several drugs that target the epigenetic machinery have emerged as attractive molecules for treating infection and inflammation by modulating macrophages. Treatment of lipopolysaccharide (LPS)-challenged macrophages with epigenetic modifiers leads to phenotype switching. This could provide stimulatory/destructive (M1) or suppressive/protective (M2) therapeutic strategies, which are crucial in the cytokine milieu in which the macrophages reside. In this review, we provide an overview of macrophage functional diversity during various diseases, including infection, as well as the current status in the development and clinical utility of epigenetic modifiers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available